Background: Interstitial lung disease (ILD) is important drug related toxicity because it commonly forced to discontinue the treatment. Methods: To characterize the prevalence and patterns of pemetrexed induced ILD, an independent ILD advisory board composed of external experts performed reassessment of ILD in two post marketing surveillance (PMS) studies for malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). Results: ILD incidences were originally 1.6% and 2.6% in 903 MPM and 683 NSCLC patients in safety analyses, respectively. Based on the reassessment by the board, the incidence was 1.1% MPM and 1.8% NSCLC. Common possible risk factors of ILD in MPM and NSCLC patients were male gender, 60 years or older age, and pre-existing ILD. Asbestosis in MPM, and smoking history in NSCLC are also considered as risk, respectively. In terms of computed tomography (CT) pattern, 7 of 10 cases in MPM patients had acute interstitial pneumonia pattern, which four were fatal. Eight of the 12 NSCLC patients had diffuse grand glass opacity, which all had recovered. Onset of ILD in MPM varied between the first and the fifth courses of pemetrexed treatment, and the latest onset was 48 days after the last administration. For NSCLC, it was between the second and the ninth course, 7 and 56 days after the last administration. Conclusions: The risk of pemetrexed-related ILD is similar level as other anti-cancer drugs under clinical settings. Careful observations continuously during and at least for 2 months after the last administration of pemetrexed are advised.
Introduction
Pemetrexed is a multi-targeted anti-folate agent that inhibits three folate-dependent enzymes: thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase, all of which are used in purine and pyrimidine synthesis (1, 2) . The methotrexate, an anti-folate agent similar to pemetrexed, is known as a causal agent of interstitial lung disease (ILD). It is also reported that the frequency of drug-induced ILD related events is higher in Japanese than the rest of the world (3) . In fact, during pemetrexed clinical trials with Japanese prior to regulatory approval, ILD was reported in 4.0% (1/25) of MPM patients and 3.6% (8/225) of NSCLC patients, of which one patient was fatal (4, 5) . Therefore, pemetrexed-related ILD is a great concern in Japan.
Pemetrexed was approved in January 2007 for malignant pleural mesothelioma (MPM), and in May 2009 for non-resectable advanced or relapsed non-small cell lung cancer (NSCLC) in Japan. Previously, we have reported safety analysis of two post marketing surveillance (PMS) studies of pemetrexed in MPM patients and in NSCLC patients, including ILD related adverse events of 1.6% (14/906) and 2.6% (18/683), respectively (6, 7) . These studies were conducted in multiple centers, and ILD related adverse events were reported by a broad range of physicians, most are non-ILD specialists. Considering the difficulty of diagnosing ILD with computed tomography (CT) and X-ray images of chests in patients with thoracic malignant tumors, it is possible that ILD cases are over-diagnosed in these studies. Hence, it is essential to characterize the true prevalence and patterns of pemetrexed-related ILDs by experts. In this report, we gathered CT and/or X-ray data of ILD cases from those two PMS studies with MPM and NSCLC patients, and then requested a multi-disciplinary expert panel consisting of radiologists, medical oncologists, pulmonologists and a pathologist to assess true ILD risks and analyze disease characteristics.
Patients and methods

Patients and post marketing surveillance study design
The data collected from pemetrexed PMS studies in MPM patients and NSCLC patients were used in this report (6, 7) . Patients treated with pemetrexed in Japanese daily clinical settings were registered between January 2007 and May 2008 in MPM study (6) , and between June 2009 and May 2010 in NSCLC study (7) . The study design was a post marketing all-case registry study for MPM (6) , and a sequential central registration system was used for NSCLC (7) . Observational periods for each patient were 6 months for MPM and 12 months for NSCLC, and when pemetrexed was discontinued before 6 or 12 months, safety information was collected until at least 30 or 60 days. The recommended dose of pemetrexed is 500 mg/m 2 administered as an intravenous infusion over 10 min on the first day (Day 1) of each 21-day cycle. For MPM patients, pemetrexed is administered as a concomitant drug with cisplatin. Among patients in these two PMS studies, patients included in safety and effectiveness analysis were also applied for statistical analysis in this report; 903 patients from MPM study and 683 patients from NSCLC study were re-assessed (6,7). These PMS studies were multi-center, non-interventional, observational studies and conducted in compliance with the regulation of Good Post-Marketing Study Practice in Japan.
Candidates for ILD assessments were selected based on ILDrelated adverse events reported by their physicians during original studies, and their CT or X-ray data were applied for further evaluation by the ILD advisory board members. Fourteen ILD cases from MPM study and 18 cases from NSCLC study were applied for further ILD assessment by the advisory board. However, one of ILD patients from NSCLC was excluded from further ILD advisory board evaluation due to the lack of CT or X-ray data (Table 1) .
ILD assessment
In order to evaluate ILD cases, a pemetrexed ILD advisory board was organized independently, comprised of external experts include two radiologists, two medical oncologists, two pulmonologists and a pathologist, and the board was organized independently. CT and/or X-ray, as well as laboratory test data of patients reported to have ILD during two PMS studies were provided to and assessed by the pemetrexed ILD advisory board as far as possible. Radiologist mainly conducted interpretation of radiogram. If histopathological sample was provided from physician, pathologist assessed and provided histopathological findings at advisory board meeting. At the annual meeting, all available data were reviewed and confirmed the diagnosis by board members. Eli Lilly employees worked as facilitator of the advisory board meeting.
The following points were assessed by the ILD Advisory Board: CT patterns cannot be classified by the above criteria, including centrilobular shadows or nodules. This also includes the pattern for non-specific interstitial pneumonia pattern (NSIP); diffuse areas of heterogeneous opacity, whereas early CT scans show diffuse GGO and late CT scans show fibrosis in a basal distribution.
Statistical analysis
Fisher's exact test was conducted to assess ILD risk factors using a two-tailed significance level of 5%. 
Results
MPM
During the 17-month enrollment, clinical physicians reported 14 (1.6%) ILD cases among 903 MPM patients in the PMS study (6) . With the assessment by the ILD advisory board, pemetrexed-related ILD was confirmed on 10 (1.1%) of these cases and three were excluded as other interstitial changes; progression of pre-existing interstitial abnormality, infection, methotrexate pneumonitis by their clinical course and one was excluded as alveolar shadow. All 10 patients were male, ranging from 57 to 78 years old. The occurrence of ILD was significantly higher in patients with pre-existing ILD (P = 0.0023) and asbestosis (P = 0.0064) than without ( Table 1 ). All ILD cases were serious, no sufficient effect of steroids treatment was observed in four cases and the outcome of these cases were fatal (Table 2) . AIP was the predominant ILD pattern shown in CT images of MPM patients; AIP patterns were clearly indicated in 7 of 10 patients ( Table 2 , Fig. 1 ). There were also one each AEP and/or AIP, NSIP and possible early stage AIP (Table 2 ). There was no clear correlation between timing of ILD onset and number of pemetrexed treatment courses (Fig. 2) . Five patients developed ILDs were with single course, two with 2-courses, one with 4-courses, and two with 5-courses of pemetrexed treatments (Fig. 2) . The earliest ILD manifestation was 3 days from the first course of pemetrexed treatment, the latest was 42 days from the fifth treatment, and the latest onset was 48 day from the last treatment (Fig. 3) .
NSCLC
During the 12-month enrollment, 18 (2.6%) ILD cases were reported by clinical physicians among 683 (first-line: 343, ≥second-line: 340) NSCLC patients in the PMS study (7) . Pemetrexed-related ILD was confirmed on 12 (1.8%) of these patients by the ILD advisory board members (Table 1) and four patients were excluded as infection and one was as tumor associated shadow. Image data of one patient was not provided by physician. Eleven of 12 patients were male, all were over 60 years old, 11 were smokers, and two had pre-existing ILD. The occurrence of ILD was significantly higher in elder (P = 0.0325) and smokers (P = 0.0194) ( Table 1) . Among 12 patients, eight cases were serious, and the other four cases were non-serious. Nine patients received steroid treatment, and most of these patients were responded to the steroid treatment and recovered, but one patient did not respond and the outcome was fatal ( Table 2) . Other serious ILD patients were recovered or recovering, but one patient did not recover as of 35 days after ILD onset. Three of four non-serious cases did not receive any steroid treatment, and two of them were recovered or recovering immediately after pemetrexed was discontinued, but one case was not recovered. One case of the rest of the non-serious cases was recovered by steroid treatment.
The predominant CT pattern was the diffuse GGO which was observed in eight cases confirmed for ILD by the ILD advisory board: Other four patients' CT patterns were one each of AIP, indeterminable, multiple patchy GGO or atypical drug-induced ILD pattern (Table 2, Figs 4 and 5) .
Eleven of 12 patients developed ILD between the second to fourth courses of pemetrexed treatment (Fig. 2) ; the other patient developed ILD at the ninth course. The latest onset after the last treatment was on Day 56 (Fig. 3) , and this patient showed no response to steroid and resulted in the death (Table 2 ).
Discussion
The aim of this report was to confirm and characterize ILD events in MPM and NSCLC patients, possibly related to pemetrexed treatment. Our findings were based on two PMS studies of these patients in a typical Japanese clinical practice setting (6,7). The incidence rate of drug-induced lung disease of gefitinib, which ILD risk assessments have conducted in clinical setting, was 4.50% (9) . For other anti-cancer drugs, ILD incidences have been reported 1-5% for methotorexate and 1.5% for gemcitabine (3) . As results of assessments by the advisory board, the incidence rate of pemetrexedrelated ILD in MPM and NSCLC patients were 1.1% (10/903 patients) and 1.8% (12/683 patients), respectively (Table 1) , and the overall mortality rates resulting from ILD were 0.44% (4/903 patients) and 0.15% (1/683 patients), respectively ( Table 2) . These numbers were not remarkably higher than the results seen with other anti-cancer agents (10, 11) , nor results reported in previous Japan clinical studies of pemetrexed (4, 5) .
The findings from this study suggested that possible risk factors of pemetrexed-related ILD in MPM and NSCLC patients were similar to those reported for other anti-cancer drugs: male, older than 60 years, and pre-existing ILD (3,9,12 ). There were also statistical differences on asbestosis in MPM patients and a smoking history for NSCLC patients that are consistent to previously known risk factors (3, 9, 12) . On the other hand, PS and prior chemotherapy which have been identified as possible risk factors in other PMS studies, gefitinib (9) or erlotinib (12), were not identified as ILD risk factors of pemetrexed treatment in either MPM or NSCLC patients. It was possible that PS and prior chemotherapy were not identified as risk factors in this report because numbers of ILD cases assessed were limited. We believe that it is important to continue providing the risk/benefit information to patients upon initiation of pemetrexed treatment. There was no clear correlation between the timing of ILD onset and increment of pemetrexed treatment cycles in both MPM and NSCLC patients. While the median of treatment cycles were between 3.5 and 4.0 in PMS studies (6, 7) , time to ILD onset was between 1 and 5 treatment cycles for MPM patients, and was between 2 and 9 cycles for NSCLC patients (Fig. 2) . It is also necessary to consider the time after the last administration. The last onset after the last pemetrexed treatment was Day 48 for MPM, and Day 56 for NSCLC. Unlike gefitinib which has ILD onset timing of~1 month (9) , timing of ILD onset in MPM and NSCLC patients are unpredictable and onset could happen even months after the pemetrexed treatments have been discontinued. Therefore, patients who were treated with pemetrexed should be carefully observed during treatments and at least 2 months after the last pemetrexed administration.
There were differences in characteristics of ILDs in MPM and NSCLC patients. In MPM patients, AIP pattern was predominant, and 4 of 10 ILD cases were fatal. In NSCLC patients, on the other hand, the diffuse GGO pattern was most dominant, and these patients responded well to steroids. Methotrexate, a similar anti-folate drug, is known to induce similar steroidresponsive ILD in rheumatic patients (13, 14) . It seems that responses to steroid therapy by ILD caused by pemetrexed in NSCLC patients are similar to ILD caused by Methotrexate in rheumatic patients.
In addition, there were four non-serious ILD cases identified among ILD of NSCLC patients unlike in MPM patients. And more, in two cases, it is possible that only discontinuation of pemetrexed without steroid treatment was sufficient for recovery from these non-serious ILD. It was also noteworthy that CT patterns of these patients showed only faint ground-glass opacity, and patients experienced no ILD related symptoms, such as pyrexia. It has been speculated that one reason for differences in CT pattern and outcome of ILD is the asbestosis. Asbestosis in MPM patients takes on a role in the drug related ILD induction, especially which leads to diffuse alveolar damage with AIP patterns. The precise mechanism underlying these differences of ILD patterns between MPM and NSCLC patients, however, remains still unclear.
There were some limitations in this study. First, these two PMS studies were conducted under daily clinical settings, so that for some cases, there was not enough data for advisory board to assess ILD. Second, these studies had different observational periods. Third, there was the possibility of bias in reporting events since reports of ILD were entirely based on clinical physicians' diagnoses. Finally, while CT patterns should be assessed with high resolution computed tomography (HRCT), HRCTs were not available for some ILD patients. In addition, the technical protocol, including voltage, electric current, field of view, and reconfiguration function for CT imaging, was not uniform among investigation sites.
In conclusion, the ILD incidence rate related to pemetrexed is not excess of other anti-cancer drugs. Unlike other anti-cancer drug like gefitinib, there appears to be no particular ILD onset timing, therefore it is necessary to observe patients for ILDs carefully during pemetrexed treatment and continuously at least 2 months after the last administration 
